TNXP
Tonix Pharmaceuticals Holding Corp.
NASDAQ · Healthcare · Biotechnology · US
$13.14
−1.72%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$225.36M
MomentumView details →
1D Return
−1.72%
YTD Return
−16.21%
RSI (14)
54.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$225.36M
RSI (14)
54.3
MomentumView details →
1D Return
−1.72%
YTD Return
−16.21%
SummaryUpdated Jun 1, 2026
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Chatham, New Jersey. The company went public in May 2012 and focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics across multiple therapeutic areas. Tonix operates as a development-stage company with a diverse pipeline of drug candidates targeting immunology, rare diseases, infectious diseases, and central nervous system conditions, though it has yet to bring any products to market and remains in the clinical development phase.
Similar companies
Latest newsMore news →
Tonix Pharmaceuticals is focusing on the commercial launch of TONMYA for fibromyalgia.18d agoDr. Seth Lederman was appointed Interim Chief Medical Officer of Tonix Pharmaceuticals Holding Corp., effective August 18, 2026, while continuing as President, Chief Executive Officer and Chairman of the Board.18d agoTonix Pharmaceuticals reported second quarter 2026 financial results, with TONMYA net sales of approximately $11 million, up 197% quarter-over-quarter, and cash and cash equivalents of approximately $176.2 million as of June 30, 2026.25d ago